Immunotherapy News and Research

Latest Immunotherapy News and Research

Immunotherapy could prevent allergic reactions to food

Researchers at National Jewish Medical and Research Center are conducting trials to evaluate a method to prevent allergic reactions to food.

17 Apr 2008

2nd Alzheimer's vaccine by AFFiRiS

The Viennese biotech company Affiris is today taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well. As a result, Affiris is among the leading international centres in the race to develop the first causal immunotherapy for Alzheimer's disease.

17 Apr 2008

Scientists create monoclonal antibody libraries against avian influenza

An international group of American and Turkish research scientists, led by Sea Lane Biotechnologies, has created the first comprehensive monoclonal antibody libraries against avian influenza (H5N1) using samples from survivors of the 2005/2006 "bird flu" outbreak in Turkey.

15 Apr 2008

Researchers find benefit for lymphoma patients in combined PET-CT scanning

Combined positron emission tomography (PET) and computed tomography (CT) imaging of lymphoma patients is a more effective method to evaluate response to radiation therapy, and may help patients avoid unnecessary follow-up treatments, a study by researchers at the University of Southern California (USC) suggests.

13 Mar 2008

Researchers find cause of severe allergic reaction to cetuximab

Clinicians have been perplexed by the fact that some patients given the drug cetuximab - an immune-based therapy commonly used to treat persons diagnosed with head and neck cancer, or colon cancer - have a severe and rapid adverse reaction to the drug.

13 Mar 2008

Allergy testing is essential in the effective management of patients with allergic conditions

When combined with a detailed medical history, it can identify the causes of allergy symptoms and provide the basis for avoidance, environmental control and immunotherapy.

11 Mar 2008

Artificial 'cells' that boost the immune response to cancer

Using artificial cell-like particles, Yale biomedical engineers have devised a rapid and efficient way to produce a 45-fold enhancement of T cell activation and expansion, an immune response important for a patient's ability to fight cancer and infectious diseases, according to an advance on line report in Molecular Therapy.

27 Feb 2008

OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer

Oregon Health & Science University Cancer Institute researchers, in a first-of-its-kind study, have found that even men with advanced prostate cancer can take a much-needed safe break, or holiday, from chemotherapy.

27 Feb 2008

Mesothelin appears to play important role in promoting pancreatic cancer growth - clues to new treatments

New understanding of a protein that spurs the growth of pancreatic cancer could lead to a new vaccine against the deadly disease, said researchers at Baylor College of Medicine in Houston in a report appearing in the current edition of the journal Molecular Cancer Therapeutics.

17 Feb 2008

New way to boost the immune system

Queen's University immunologists have discovered how to manipulate the immune system to increase its power and protect the body from successive viral infections.

23 Jan 2008

Body's immune system uses common molecule to recognize prostate tumors

In experiments with mice, researchers have found that the body's immune system can use a surprisingly common molecule to recognize prostate tumors.

11 Jan 2008

Investigational treatment for advanced melanoma to be studied

University of Illinois at Chicago researchers are participating in a multi-center research trial to evaluate the safety and effectiveness of Allovectin-7, an investigational treatment for advanced melanoma.

10 Jan 2008

Immunotherapy - How does immunotherapy work? When is immunotherapy helpful?

Those who suffer from allergic asthma, rhinitis, conjunctivitis or stinging insect allergies may be good candidates to receive immunotherapy, also known as "allergy shots," according to the American Academy of Allergy, Asthma & Immunology (AAAAI).

10 Jan 2008

New immune system discovery will help fight hay fever and other allergies

A mechanism which can lead to hay fever and other allergic reactions, by preventing the immune system from regulating itself properly, has been discovered by scientists.

28 Dec 2007

Advanced melanoma - new treatment

20 Dec 2007

ImmunoVaccine Technologies to acquire Immunotope

ImmunoVaccine Technologies Inc. (IVT), a Nova Scotia-based vaccine enhancement company, has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of cancer and infectious diseases.

10 Dec 2007

FDA approves trial for SKCC breast cancer vaccine

The Federal Drug Administration announced Friday approval of a Phase 1 clinical trial designed to study a breast cancer vaccine developed at the Sidney Kimmel Cancer Center.

10 Dec 2007

Vaccine improves event-free survival for leukemia patients

Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

10 Dec 2007

Lymphatic vessel and lymph node function are restored with growth factor treatment

The frequent spread of certain cancers to lymph nodes often necessitates surgery or radiation therapy that damages the lymphatic system and can cause lymphedema, a condition of localized fluid retention that often increases susceptibility to infections.

4 Dec 2007

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007